These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Cis-platinum: a new anticancer agent. Williams CJ; Whitehouse JM Br Med J; 1979 Jun; 1(6179):1689-91. PubMed ID: 380759 [No Abstract] [Full Text] [Related]
27. Peripheral neuropathy and ototoxicity of dichlorodiamineplatinum: instrumental evaluation. Preliminary results. Carenza L; Villani C; Framarino dei Malatesta ML; Porta RP; Millefiorini M; Antonini G; Bolasco P; Bandiera G; Marzetti L Gynecol Oncol; 1986 Oct; 25(2):244-9. PubMed ID: 3019845 [TBL] [Abstract][Full Text] [Related]
28. [Ototoxicity following the administration of high doses of cisplatin in children with malignant neoplasms]. Stura M; Perin GP; Dini G; Dallorso S; Squazzini G; Tacchino A; Tarantino V; De Bernardi B Pediatr Med Chir; 1985; 7(6):851-4. PubMed ID: 3837255 [TBL] [Abstract][Full Text] [Related]
29. Cisplatin ototoxicity. Malhotra H Indian J Cancer; 2009; 46(4):262-3. PubMed ID: 19749455 [No Abstract] [Full Text] [Related]
30. Phase I clinical trial of weekly administration of 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213). Creaven PJ; Newman SJ; Selawry OS; Cohen MH; Primack A Cancer Chemother Rep; 1974; 58(6):901-7. PubMed ID: 4615787 [No Abstract] [Full Text] [Related]
31. Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in advanced adenocarcinoma of the ovary. Wiltshaw E; Kroner T Cancer Treat Rep; 1976 Jan; 60(1):55-60. PubMed ID: 1000519 [TBL] [Abstract][Full Text] [Related]
32. Effects of azathiprine in a disorder of uric acid metabolism and cerebral function. Nyhan WL; Sweetman L; Carpenter DG; Carter CH; Hoefnagel D J Pediatr; 1968 Jan; 72(1):111-8. PubMed ID: 5634933 [No Abstract] [Full Text] [Related]
34. Hearing impairment after prolonged dihydrostreptomycin treatment of surgical tuberculosis. Lerche S Scand J Respir Dis; 1972; 53(1):27-34. PubMed ID: 4115288 [No Abstract] [Full Text] [Related]
35. Phase I clinical trial of a single-dose and two weekly schedules of ICRF-159 (NSC-129943). Creaven PJ; Cohen MH; Hansen HH; Selawry OS; Taylor SG Cancer Chemother Rep; 1974; 58(3):393-400. PubMed ID: 4601669 [No Abstract] [Full Text] [Related]
36. Effect of nandrolone phenylpropionate (NSC-23162e) on the bone marrow suppression caused by cyclophosphamide (NSC-26271): a clinical trial. Burn JI; Cooke WM Cancer Chemother Rep; 1974; 58(6):867-70. PubMed ID: 4615786 [No Abstract] [Full Text] [Related]
39. The use of high-frequency audiometry increases the diagnosis of asymptomatic hearing loss in pediatric patients treated with cisplatin-based chemotherapy. Abujamra AL; Escosteguy JR; Dall'Igna C; Manica D; Cigana LF; Coradini P; Brunetto A; Gregianin LJ Pediatr Blood Cancer; 2013 Mar; 60(3):474-8. PubMed ID: 22744939 [TBL] [Abstract][Full Text] [Related]
40. Progressive hearing loss after completion of cisplatin chemotherapy is common and more pronounced in children without spontaneous otoacoustic emissions before chemotherapy. Weissenstein A; Deuster D; Knief A; Zehnhoff-Dinnesen AA; Schmidt CM Int J Pediatr Otorhinolaryngol; 2012 Jan; 76(1):131-6. PubMed ID: 22104469 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]